560 results about "Hepatitis b viral" patented technology

The invention describes a health product additive and preparation for sots or hepatitis B pathogen carriers By adding medicinal fungus fermentation liquor as additive and using effective components and fine powder extracted from plants and herbal medicines by solvent as adjuvant, the health product can be made into forms of effervescent tablet, buccal tablet, chewable tablet, oral taken tablet, candy, chocolate, chewing gum, oral liquid, particle, soluble granules, capsule, aerosol, liquid beverage and solid beverage. The product can relieve alcohol effect, nourish stomach, protect liver, and help to remit hepatitis B virus and hepatitis liver cancer patient condition, achieves a quite important effect for protecting the health of the sots or hepatitis B pathogen carriers in daily or social occasions. The invention provides a good idea to the utilization of the large amount of active fermentation liquid generated with the thallus pharmacy in the medicinal fungus fermentation industries, and also provides a effective approach for increasing the utilization value of the large amount of wild plant resources such as wild jujube and haw widely distributed in the north areas.

The invention relates to an enantiomorphic amine alkyl sesquiterpene alcohol and glucoside and the medicated salt or solvent thereof, as well as the effect and activity of the composed medicine combination, mainly relating to the medical use in reducing HBV-DNA replication activity. And it has considerably strong inhibiting effect on HBsAG screted by HepG2.2.15 and HBV-DNA replication as compared with positive contrast Lamivudine; and it has obvious inhibition activity to HBV-DNA replication at large dosage (100 mug / mL) and medium dosage(20 mug / mL) as contrasted with Lamivudine, and can be expected to apply to preparing medicines for curing HB virus infection disease.

The invention relates to a hemiterpene derivant 2-Hydroxyilicic acid, as formula (1) 2beta-hydroxy-5alphaH-eudesmane-11(13)-allyl-12-acid and relative compounds which can be used to prepare the drug treating hepatitis B disease. The inventive compound can restrain the copy of hepatitis B surface antigen (HBsAg) and the hepatitis B deoxyribonucleic acid (HBV-DNA), while its HBsAg restrain ability is higher than positive contrast difuradin; in the density as 100mug / ml, 20mug / ml, and 4mug / ml, it can restrain the copy of hepatitis B virus HBV-DNA.

The present invention relates to an eudesmane type sesquiterpene derivative 1 beta-hydroxyilicic acid, namely 1 beta-hydroxy-5 alpha H-eudesmane-11 (13)-ethylene-12-acid, its medicineal salt or solvent compound and its medicine composition and medicinal application for preparing medicine capable of curing hepatitis B virus infective disease and resisting hepatitis B virus. Said invention also provides its chemical structure formula.

The invention involves novel drug use of six-rowed chrysanthemum plant extracts which is used to treating herpes simplex virus (type 1 and / or type 2) and various disease caused by hepatitis B virus infection. The six-rowed chrysanthemum plant extracts is prepared by six-rowed chrysanthemum plant fresh or dry goods through the refining of alcohol-water extraction, column chromatography, alcohol solvent elution, the amount of caffeoyl guinic acid chemical compound is below 30%. The six-rowed chrysanthemum plant extracts prepared in the invention has significant function of inhibiting herpes simplex virus with type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and hepatitis B virus (HBV) replication, and can reduce effectiveness of HBV e antigen (HBeAg) in the HepG 2.2.15 cell lines, it can be used for treatment various disease caused by said correlate virus infection.

The invention belongs to the field of genetic engineering, and particularly relates to a method for specifically knocking out hepatitis b virus cccDNA by using CRISPR-Cas9 and sgRNA for specifically targeting the hepatitis b virus cccDNA. The invention provides a method for specifically knocking out hepatitis b virus cccDNA by using CRISPR-Cas9 and sgRNA for specifically targeting the hepatitis b virus cccDNA. The sgRNA of specific targeted hepatitis b virus cccDNA prepared according to the invention can precisely target hepatitis b virus cccDNA and realize gene knockout. A preparation method is simple in steps and good in sgRNA targeting, and the knockout efficiency of a CRISPR-Cas9 system is high.

The invention relates to the medicine technical field and concretely relates to a mixture formed by two enantiomorphous eremophilane acids separated from murrey ligularia and the officinal salt as well as the medicine combined material. The enantiomorphous eremophilane acid can be used for preparing the medicine curing hepatitis B virus infectious diseases due to the ability of suppressing the antigenic activity on the surface of hepatitis B virus.

The invention relates to a silibinin monoester derivative and its medicine salt or solvates. The invention also relates to its preparation method and its drug combination and medical application. The compound can inhibit activity of hepatitis b virus, so it is expected to be used as drug to treat hepatitis b virus and relevant virus diseases. The compound can protect liver and is expected to be used as drug preventing liver damage. The compound possesses effect anti free radical and is expected to be used as drug treating diseases caused by free radical.

The invention belongs to the technical field of bio-macromolecular pharmaceutical preparations, and specifically relates to a DNA, a plasmid and a preparation capable of directionally clearing HBV (Hepatitis B virus) ccc in hepatocyte. According to the invention, five brand-new CRISPR / Cas systems are discovered through wide and in-depth studies, and can effectively clear HBV ccc DNA in cells, inhibit reproduction of HBVs, and reduce expression of proteins related to the HBVs. A pH-sensitive and PEG-modified cationic lipid carrier is further prepared, and has the advantages of good stability and high transfection efficiency; and internal instability of multiple cationic lipid carriers is overcome. The CRISPR / Cas systems are combined with the pH-sensitive and PEG-modified cationic lipid carrier to prepare a CRISPR / Cas9 cationic lipid carrier preparation which can effectively inhibit virus reproduction in a murine model suffering from acute HBV infection and reduce antigen expression level.

The invention discloses a fluorescent microsphere immunochromatographic testing card for testing five indexes of hepatitis b and a method for preparing the same. The testing card comprises a hepatitis b surface antigen test paper strip, a hepatitis b e surface antigen test paper strip, a hepatitis b surface antibody test paper strip, a hepatitis b e surface antibody test paper strip, and a hepatitis b core antibody test paper strip. Each test paper strip is formed by overlapping and bonding filter paper, a sample pad, a glass fiber film spray-coated with fluorescent microspheres, a cellulose nitrate film and water absorption paper on a bottom plate by glue in sequence, wherein the cellulose nitrate film is coated with antigens serving as a testing area and anti-rabbit antibodies serving as a quality control area; and during a test, after emitted fluorescent light passes a filter, the emitted spectrum is collected, accumulated and multiplied by the CCD scanning technology and then converted into a numerical signal, the numerical signal is multiplied by a correction factor, and the strength of the corrected fluorescent light is substituted in a standard curve of a fluorescence analyzer, so that the concentrations of the five indexes of hepatitis b of the sample can be automatically worked out. The test of hepatitis b viruses by the testing card has the characteristics of specificity, sensitivity, simpleness and accuracy.

The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.

The invention discloses a gRNA sequence. The sequence is capable of editing a DNA sequence in the manner of taking a hepatitis B viral genome specific locus as a target sequence. The invention also discloses a CRISPR-SaCas9 system containing the gRNA sequence and a recombinant adeno-associated virus packaged with the system. The system and the packaging virus show higher HBV scavenging activity in cells and in transgenic mice body. On the 38th day after twice continuous high dose injection, the contents of HBsAg and HBeAg in experimental group mice serum, compared with the control group, are respectively reduced by 62.96+ / -7.59% and 65.18+ / -3.08%; the HBV DNA content in the serum, compared with the control group, is reduced by 92.82+ / -3.67%; the liver and other visceral organs of the experimental mice are all free from any pathologic change, the off-target effect is also not detected and the application prospects of the gRNA sequence and the corresponding CRISPR-SaCas9 system provided by the invention in preparing the hepatitis B therapeutics are shown.

The invention belongs to the traditional Chinese medicinal material field, and relates to a Turpinia arguta leaf extract, which contains a flavonoid chemical constituent and acceptable salt in the medicine thereof. The content of total flavonoids is more than 15 percent; the content of apigenin aglycon and a flavone glycoside constituent which uses apigenin as aglycon is no less than 1.5 percent measured in the apigenin; a flavonoid chemical constituent contains one or more of the apigenin, apigenin-7-O-Bata-neohesperidoside, apigenin-7-O-2<1>-Bata-rhamanopyranosyl rutinoside, apigenin-7-O-Bata-glucoside, luteolin-7-O-Bata-glucoside. The invention furhter provides a method for preparing the extract thereof, a method for controlling the quality of the extract, and the application of the extract for preparing the medicines such as antibiosis, oxidation resistance, anti-mutation, antitumor, hepatic protection, anti-hepatitis b virus, anti-thrombosis, anti-arteriosclerosis, etc.

The invention relates to application of ring A dioxane flavonolignan in preparing medicaments for resisting hepatitis B viruses (HBV), in particular to application of ring A dioxane coupling type flavone lignan or a pharmaceutically acceptable salt thereof in preparing medicaments for clearing away hepatitis B e antigen (HBeAg), suppressing the HBV DNA replication and treating HBV infection diseases. The flavonolignan has certain activity on resisting the HBeAg, and the intensity of the flavonolignan for clearing away the HBeAg is higher than that of Lamivudine which is a positive control and close to that of 10,000 units / milliliter of alpha-interferon. Meanwhile, the suppression ratio of the compound to the HBV DNA replication is higher than 80 percent in the presence of a concentration of 100 micrograms / milliliter. The pharmacodynamical results indicate that the flavonolignan or the pharmaceutically acceptable salt thereof can be expected to be used for preparing the medicaments for clearing away the HBeAg, suppressing the HBV DNA replication and treating the HBV infection diseases.

The invention relates to an application of benzo-phenylpropanoids in preparing drugs for treating viral hepatitis B, in particular to two benzo-phenylpropanoids or application of pharmaceutically acceptable salt thereof in preparing drugs for inhibiting the replication of hepatitis B virus desoxyribonucleic acid (HBV DNA) and treating hepatitis B virus infection diseases. The two benzo-phenylpropanoids definitely inhibit the activity of the HBV DNA, have the replication inhibition activity on the HBV DNA at high dose (100 microgrammes / milliliter) of 1.3-2.2 times higher than the inhibition activity at the highest concentration (10000 units / milliliter) of an alpha-interferon and belong to an efficient non-nucleoside natural product inhibiting the hepatitis B viruses; pharmacodynamics results show the application of the benzo-phenylpropanoids or the pharmaceutically acceptable salt thereof capable of preparing the drugs for inhibiting the replication of the HBV DNA and treating the hepatitis B virus infection diseases in anticipation.

The invention relates to a method for preparing the suaveolic round leaf extractive which contains celery element or the chromocor compound with celery element as corn, or relative salt. The invention also provides relative quality control method, while said extractive can be used to prepare the drug for treating virus B hepatitis, thrombus, cancer, or the like.

The invention relates to application of diallyl propyl flavonolignan in preparation a medicament for curing hepatitis B, in particular to application of a flavonolignan or pharmaceutically acceptable salts thereof in preparation of the medicament for curing the hepatitis B by clearing hepatitis B e-antigen and inhibiting HBV DNA replication. The flavonolignan has hepatitis B virus e-antigen (HBeAg) inhibiting activities, and has the inhibition strength higher than a positive control first-line medicament, namely lamivudine and alpha-interferon, at a low concentration of 20 mu g / ml; simultaneously, at the concentration of 5 mu g / ml, the compound has an inhibition rate of the HBV DNA of over 70 percent; and therefore, the flavonolignan can be expected for preparing the medicament for curing the hepatitis B virus infection diseases by clearing the hepatitis B e-antigen and inhibiting the HBV DNA replication.

An immunoadjuvant used to prepare the antiviral vaccine or medicine for increasing the immune activity of the antigens for HBV, HCV, SARS coronavirus, fowl influenza virus, etc is a kind of human or animal's novel heat shock proteins gp96, hsp108 and hsp70.

The invention provides a set of new geldanamycin derivatives and the preparation method thereof, which also provides a drug combination using the compound as an active component. The experimental results prove that the derivatives have broad-spectrum antiviral activity, which have stronger inhibition on HIV-1 and HBV and have better inhibitory activity on herpesvirus. Owing to the inhibition on Hsp90, the compound is effective in antivirus and antitumor at the same time.

The invention discloses a graphene modified natural emulsion preparation method and a high barrier condom. The graphene modified natural emulsion preparation method and the high barrier condom have the beneficial effects that firstly graphene and a dispersing agent mixed liquor are mixed, ground and stirred and then the product is mixed in a natural emulsion aqueous solution, so that graphene can be uniformly dispersed in emulsion and the strength of a natural emulsion composite material is improved; meanwhile, the number of micropores is smaller due to the graphene / emulsion composite action, thus greatly reducing the virus penetration probability; the thickness of the graphene condom can be 5-80mu m, so that the use requirements of the condom can be met; dense high barrier packing layers are formed by the composite crosslinked nano-packing technology, so that the natural gaps among molecules are reduced; therefore not only can HIVs be blocked but also hepatitis B viruses, hepatitis C viruses, human papilloma viruses, and the like, and most harmful bacteria, which are smaller than the HIVs, can not pass through the micropores.

The invention belongs to the field of antivirus in medical chemistry, and relates to preparation of non-cyclic nucleotide phosphoamides and salts thereof and application of the non-cyclic nucleotide phosphoamides and salts thereof in treating human immunodeficiency virus (HIV), hepatitis B, hepatitis B virus (HBV) and other virus infection diseases. The non-cyclic nucleotide phosphoamides, and isomers, pharmaceutically acceptable salts, hydrates, solvates or crystals thereof have the general formula I of which the structure is disclosed in the specification. The invention also provides a pharmaceutical composition containing the compounds and isomers, pharmaceutically acceptable salts, hydrates, solvates or crystals thereof, and application of the compounds or composition in treating and / or preventing HIV and HBV infection. The compounds provided by the invention have the advantages of favorable anti-HIV and HBV activities, low oral dosage and low toxicity.

The invention relates to an anti-hepatitis B virus tertiary amine oxide and preparation method and uses for manufacturing drugs, wherein the tertiary amine oxidate has a structure represented by general formula (I) and (II), its preparing process comprises the compound having general formula (I) is prepared through condensation of derivatives of amine with acidamide and further oxidation, the compound having general formula (II) is prepared through the condensation between mono-hydrocarbyl piperazidine with carboxylic acid or carboxylic acid derivatives, or through alkylation of piperazine amidos and further oxidization. The compound can be used for preparing medicament for preventing or treating hepatitis B virus related diseases.

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and / or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and / or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and / or develop or design agents capable of inhibiting infection, replication and / or release of the virus.

The invention provides a phenanthridine compound with an effect of resisting hepatitis B and hepatitis C, a medicinal composition taking the same as an active medicine component, a preparation method and applications of the phenanthridine compound in preparing a medicine for resisting hepatitis C viruses, and preparing an anti-virus medicine. According to the invention, the activity of benzylphenethylamine alkaloid in resisting various viruses is discovered in a process of studying a plant anti-virus natural product, and an obvious effect in resisting viruses of hepatitis B and hepatitis C of a phenanthridine derivative is discovered through structure modification, structure-function relationship and structure optimization.

This application relates to a purine derivative and pharmaceutical compositions which are useful for treating a hepatitis B viral infection or a hepatitis C viral infection.

The invention provides preparation and application of an electrochemical micro-fluidic device for nucleic acid isothermal amplification. A micro-fluidic electrochemical sensor device is directly established on a printed electrode. The device comprises two layers of PDMS chip. The micro-channels on the upper layer are used to fully mix various samples. The channel area in the lower layer is divided into a reaction area and a detection area. A temperature-control element is integrated to the device. The electrode surface is subjected to functional modification. Corresponding primers aiming at the hepatitis B virus nucleic acid are designed. Electrochemical reporter molecules are grafted onto the primers. The labeled primers and the nucleic acid to be detected are evenly mixed, then the mixture is injected into a micro-fluidic chip, and a proper temperature is controlled to carry out isothermal amplification reactions on the nucleic acid sample. The labeled primers are combined to the electrode surface through the base pairing effect during the amplification process. Then the virus can be detected through the detection on the reporter molecules. The provided device has the advantages of miniaturization, low cost, and portability, can perform rapid and high-sensitive detection, and is convenient for diagnosis in outdoors / home.

The invention relates to an application of tetrahydroindolone / tetrahydroindazolone / tetrahydrocarbazole derivatives and salts thereof in the preparation of antiviral drugs. The tetrahydroindolone derivatives, the tetrahydroindazolone derivatives or the tetrahydrocarbazole derivatives, as well as the salts thereof of the invention have anti-viral functions, and the virus comprises I-typed and II-typed herpes virus, coxsackie virus type 3 (CVB3) and hepatitis B virus.

The invention discloses a method of diagnosing hepatitis B virus (HBV) infection by combined detection for HBV related pre-S1 antigen (HBV PreS1) and core antigen (HBcAg). And the invention also discloses a method for detecting HBV PreS1 by double-antibody sandwich method. And the invention also discloses a reagent box and virus lysate for the above detection and their uses.

The invention provides a small interference RNA molecule SiRNA capable of attacking human hepatitis B virus, which is double chain RNA molecule whose sequence has at least 70% of consanguinity degree with the sequence (I), wherein the antisense chain of the sequence (I) and one nucleic acid mutant has no consanguinity with the known human gene and gene expression segment. The SiRNA can be used for preparing medicament or preparation for prevention or treating hepatitis B and any diseases relating to hepatitis B viral infection.

The invention discloses the medical application of a 15-methylene replaced andrographolide derivant as shown in general formula 1, more particularly relates to the application thereof in preparing anti-hepatitis B virus drugs, pertaining to the pharmaceutical chemistry field. HepG2.2.15 cells are used for detecting the secretory volumes of HBsAg and HBeAg and the HBV DNA level related to viral particles in the supernatant liquid of a nutrient solution, and the result shows that the 15-methylene replaced andrographolide derivant has good in-vitro anti-HBV effect. The 15-methylene replaced andrographolide derivant has better development and application prospect by being applied in preparing drugs used for treating and preventing Hepatitis B.